Basel, Switzerland

Bindhumadhavan Gururajan

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2020-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Bindhumadhavan Gururajan

Introduction

Bindhumadhavan Gururajan is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug formulations. With a total of 3 patents to his name, Gururajan continues to push the boundaries of medical science.

Latest Patents

One of his latest patents is focused on the formulation of ribociclib tablets. The present disclosure is directed to an oral tablet of ribociclib, including its salt(s). One embodiment of this patent is aimed at creating a tablet of ribociclib with a high drug load and an immediate release profile. Additionally, another embodiment involves a coated tablet of ribociclib, where the coating serves as an aqueous moisture barrier coating, such as Opadry® amb II, which is PVA based. This innovative approach enhances the stability and effectiveness of the drug.

Career Highlights

Gururajan is currently employed at Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to collaborate with some of the brightest minds in the industry, contributing to groundbreaking advancements in drug development.

Collaborations

Some of his notable coworkers include Arnaud Grandeury and Rui Costa. Their collective expertise fosters an environment of innovation and creativity, driving the development of new pharmaceutical solutions.

Conclusion

Bindhumadhavan Gururajan's contributions to the field of pharmaceuticals through his patents and collaborations highlight his commitment to advancing medical science. His work continues to impact the industry positively, paving the way for future innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…